The Moderna GSK patent settlement, signed on 28 October 2026 and disclosed by Moderna on 6 November 2026, ends every dispute between the two companies pending in the United States and Europe. The companies granted each other patent cross-licences in the field of infectious disease, and neither side is obliged to make any payment under those licences.
The deal matters because it breaks the pattern of recent messenger ribonucleic acid (mRNA) vaccine settlements, where the accused company paid hundreds of millions of US dollars.
What happened
GSK filed 2 complaints against Moderna in the District of Delaware on 15 October 2024, as summarised at the time by Goodwin. The first accused the Spikevax COVID-19 vaccine of infringing 7 US patents and sought damages and an ongoing royalty. The second targeted the mRESVIA respiratory syncytial virus (RSV) vaccine under 6 patents and also asked for an injunction. The asserted patents concern mRNA and lipid formulations, the way they are produced and their use as vaccines.
Reuters reports that the settlement also covers the newer mNEXSPIKE COVID-19 vaccine. A joint filing in Delaware on 6 November 2026 seeks dismissal of the US claims with prejudice, which means GSK cannot bring them again.
Moderna’s results statement says the cross-licences are limited to infectious disease and that the parties “are not obligated to make payments of any kind” under them. No other terms were published, so the scope of each licence and the patents it covers remain unknown.
The settlement does not end all of GSK’s mRNA litigation. According to Reuters, GSK’s separate 2024 lawsuit against Pfizer and BioNTech over their COVID-19 vaccine is still pending. For Moderna, the deal removes a dispute that reached both its COVID-19 franchise and its RSV product.
A pattern in mRNA settlements, with one difference
Two earlier settlements show what usually happens when an mRNA or delivery patent owner sues a vaccine maker.
On 3 March 2026, Genevant Sciences and Arbutus Biopharma announced a global settlement with Moderna worth up to USD 2.25 billion. Moderna agreed to pay USD 950 million, due in July 2026, and a further USD 1.3 billion if an appeal on the government-contractor defence under 28 U.S.C. § 1498 goes against it. Genevant granted a global non-exclusive licence to its lipid nanoparticle (LNP) technology for SM-102-containing infectious disease vaccines.
On 8 August 2025, CureVac and GSK resolved their US litigation with BioNTech and Pfizer. The 2 claimants shared USD 740 million and will receive single-digit royalties on later US COVID-19 vaccine sales. BioNTech and Pfizer received a non-exclusive licence.
Both deals moved money in one direction, and the published terms show licences flowing only to the defendant. The GSK settlement is different on its face: licences went both ways and no payment is due under them.
The wider picture in mRNA patents
Three related developments show how contested this field has become.
First, validity is fragile. On 5 March 2025 the Patent Trial and Appeal Board (PTAB) found all challenged claims of 2 Moderna COVID-19 vaccine patents, US 10,702,600 and US 10,933,127, unpatentable as obvious. The inter partes reviews were brought by Pfizer and BioNTech, as reported by Crowell & Moring. Even core vaccine patents can fall in inter partes review.
Second, the field is consolidating. On 18 December 2025, BioNTech closed its acquisition of CureVac, bringing a long-time litigation opponent and its patents inside the group.
Third, claimants are not only companies. On 16 October 2024, a day after GSK sued, Northwestern University filed its own Delaware action against Moderna over 3 LNP patents, according to the same Goodwin summary. Universities with early delivery research are also asserting rights over commercial vaccines.
What it means for mRNA developers and vaccine makers
For companies with their own mRNA and LNP patents, the GSK settlement suggests that a defensive portfolio can secure freedom to operate without cash. That only works if the portfolio reads on the other side’s products, so mapping claims against competitors’ vaccines is worth doing before any dispute starts.
For smaller developers without such a portfolio, the lesson is less comfortable. Access to foundational LNP and mRNA formulation patents is still likely to cost money, as the Genevant and CureVac deals show.
Scope also matters. The cross-licences cover infectious disease only. Companies moving mRNA into oncology, rare disease or autoimmune disease, the area behind the Novartis-Abogen mRNA deal of October 2026, should not assume that vaccine licences will reach their programmes. A freedom to operate search and a landscape of the LNP and formulation patents in their target field are practical starting points.
Synoptic IP’s view
Synoptic IP’s view is that the Moderna GSK patent settlement may signal a shift among the large mRNA players from litigation towards trading rights. The reasons are in the facts above. Two companies that had both built mRNA portfolios settled with licences in both directions and no payment due under them. By contrast, the Genevant and CureVac settlements, where licences flowed one way, cost the defendants hundreds of millions of US dollars.
The strongest counter-argument is that one no-payment deal proves little. A mutual walk-away could reflect doubts about validity on both sides rather than balanced strength, and the terms are unpublished. Major cases also remain active, including GSK against Pfizer and BioNTech, and Genevant and Arbutus against the same defendants after a favourable claim construction ruling in September 2025.
That objection limits the view but does not overturn it. Where both sides hold patents that read on each other’s products, trading rights appears able to replace cash. Where they do not, the earlier settlements suggest the party needing a licence pays. The field-of-use limit to infectious disease means any such balance may not extend to other therapy areas.
If your team is developing mRNA or LNP products, our freedom to operate searches and patent landscape analysis can show where licences may be needed before a dispute begins.
This article is commentary and opinion based on public reports as of 11 November 2026 and is not legal advice.